Innovation Pharmaceuticals Inc (IPIX)

[cabel]

We don't have the data for that (yet). All we know is B met the primary endpoint and was the statistical equal of Daptomycin at that point. Unless someone knows something I don't, your question cannot be answered until more information is available.

A single dose regimen has been selected for phase 3 and plans are being made to move forward. We also know from an earlier PR that all 4 arms combined had a better response at 7 days in the p2b than the p2a. While I would feel more comfortable with data in hand, it may be a while before we get to see it.

I am curious,.... these results were based on 2-3 days after dosing started, and we showed that we were not inferior to Dapto,... yet one of our arms plus the Dapto arm were not even finished dosing at that time.

On top of that, Leo announces plans to use the one day dose for Phase 3, without releasing to us the data results for 7, 10, and 28 days.

Perhaps it is Leo's way of saying,... wink, wink, nod, nod!! We know the results of the 7, 10, and 28 days,...?